NCT00379288已完成3 期
A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroids
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 404
- 主要终点
- The Number of All Randomized Subjects Reporting Adverse Events (AEs).
研究概览
简要总结
The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol combination (F/SC) (250/50 mcg BID and 500/50 mcg BID) in subjects with persistent asthma who require maintenance treatment on inhaled glucocorticosteroids (ICS); evaluator-blind.
In addition, the extrapulmonary effects on 24-hour plasma cortisol area under curve (AUC), of MF/F MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, F/SC MDI 250/50 mcg BID, and F/SC MDI 500/50 mcg BID will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of either sex and any race, at least 12 years of age, with a diagnosis of asthma of at least 12 months.
- •Use of medium or high daily dose of ICS (alone or in combination with long-acting beta-agonist [LABA]) for at least 12 weeks prior to Screening and have been on a stable regimen for at least 2 weeks prior to Screening.
- •Medium daily doses of ICS:
- •> 500 to 1000 mcg beclomethasone chlorofluorocarbon (CFC)
- •> 250 to 500 mcg beclomethasone hydrofluoroalkane (HFA)
- •> 600 to 1000 mcg budesonide dry powder inhaler (DPI)
- •> 1000 to 2000 mcg flunisolide
- •> 250 to 500 mcg fluticasone
- •400 mcg MF
- •> 1000 to 2000 mcg triamcinolone acetonide
- •High daily doses of ICS:
- •> 1000 mcg beclomethasone CFC
- •> 500 mcg beclomethasone HFA
- •> 1000 mcg budesonide DPI
- •> 2000 mcg flunisolide
- •> 500 mcg fluticasone
- •> 400 mcg MF
- •> 2000 mcg triamcinolone acetonide
- •If there is no inherent harm in changing the subject's current asthma therapy, the subject must discontinue prescribed ICS or ICS/LABA combination at Baseline.
- •Must show evidence of reversibility within the last 12 months or during the Screening Period. Historical reversibility defined as an increase in absolute forced expiratory volume in 1 second (FEV1) of >= 12% and >= 200 mL will qualify if performed within 12 months of Screening. If no historical reversibility, subject must demonstrate an absolute FEV1 of >= 12% and >= 200 mL within 10 to 15 minutes after four puffs of salbutamol at Visit 1 or anytime prior to Baseline.
- •At Screening and Baseline, FEV1 must be >= 50% predicted, when restricted medications are withheld for the appropriate intervals.
- •Complete blood count, blood chemistries, urinalysis, and electrocardiogram (ECG) conducted at Screening must be within normal limits or clinically acceptable to the investigator/sponsor. A chest x-ray performed at Screening or within 12 months prior must be clinically acceptable.
- •A female of childbearing potential must be using a medically acceptable, adequate form of birth control:
- •prescribed hormonal contraceptives;
- •medically prescribed intrauterine device (IUD);
- •medically prescribed transdermal contraceptive;
- •condom in combination with spermicide;
- •monogamous relationship with a male partner who has had a vasectomy.
- •Birth control must have started at least 3 months prior to Screening. Subject must agree to continue its use for the duration of the study. A subject of childbearing potential who is not currently sexually active must agree to use a medically acceptable method should she become sexually active during the study. Women who have been surgically sterilized or are at least 1 year postmenopausal are not considered to be of childbearing potential. A subject of childbearing potential must have a negative serum pregnancy test at Screening.
排除标准
- •A change (increase or decrease) in absolute FEV1 of > 20% at any time from the Screening Visit up to, and including, the Baseline Visit.
- •A subject who requires the use of > 12 inhalations per day of short-acting beta-agonist (SABA) MDI or > 2 nebulized treatments per day of 2.5 mg salbutamol, on any 2 consecutive days from the Screening Visit up to, and including, the Baseline Visit.
- •A subject who experiences a clinical asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication [other than SABA]) at any time from the Screening Visit up to, and including, the Baseline Visit.
- •A subject who has ever required ventilator support for respiratory failure secondary to asthma.
- •A subject who is a smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history > 10 pack-years.
研究组 & 干预措施
F/SC 500/50 mcg BID
Active Comparator
干预措施: Fluticasone/Salmeterol 500/50 mcg BID (Drug)
MF/F 200/10 mcg BID
Experimental
干预措施: mometasone furoate combination MDI 200/10 mcg BID (Drug)
MF/F 400/10 mcg BID
Experimental
干预措施: mometasone furoate combination MDI 400/10 mcg BID (Drug)
F/SC 250/50 mcg BID
Active Comparator
干预措施: Fluticasone/Salmeterol 250/50 mcg BID (Drug)
结局指标
主要结局
The Number of All Randomized Subjects Reporting Adverse Events (AEs).
时间窗: 1 year
AEs that are considered Related, Severe, and Serious, as determined by the investigator and using specific criteria defined in the protocol, are included in the primary results.
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)AsthmaNCT02741271Organon and Co181
已完成
3 期
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPDPulmonary Disease, Chronic ObstructiveNCT01192191GlaxoSmithKline187
已完成
3 期
Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)Rhinitis, Allergic, SeasonalNCT03882047Organon and Co313
已完成
2 期
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent AsthmaAsthmaNCT01555151Novartis Pharmaceuticals739
未知
2 期
OSKIRA-Asia-1XRheumatoid ArthritisJPRN-jRCT2080221945AstraZeneca